Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations
The introduction of Direct Oral Anticoagulants (DOACs) to the pharmaceutical market provided patients and clinicians with novel convenient and safe options of anticoagulation. The use of this class of medications is currently limited to venous thromboembolic therapy and prophylaxis, in addition to s...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2019/4383269 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565437011853312 |
|---|---|
| author | Sherif Elhosseiny Hassan Al Moussawi Jean M. Chalhoub James Lafferty Liliane Deeb |
| author_facet | Sherif Elhosseiny Hassan Al Moussawi Jean M. Chalhoub James Lafferty Liliane Deeb |
| author_sort | Sherif Elhosseiny |
| collection | DOAJ |
| description | The introduction of Direct Oral Anticoagulants (DOACs) to the pharmaceutical market provided patients and clinicians with novel convenient and safe options of anticoagulation. The use of this class of medications is currently limited to venous thromboembolic therapy and prophylaxis, in addition to stroke prophylaxis in patients with nonvalvular atrial fibrillation. Despite their altered hemostasis, patients with cirrhosis are thought to be in a procoagulant state and thus prone to thrombus formation. Patients with cirrhosis might benefit from the convenience of DOACs; however, the medical literature includes limited data on the efficacy and safety of DOACs in this special patient population. The aim of this review is to summarize the current evidence for anticoagulation options in patients with cirrhosis and their safety profile. |
| format | Article |
| id | doaj-art-31c902b942e04026aee1cf884e27e3e4 |
| institution | Kabale University |
| issn | 2291-2789 2291-2797 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-31c902b942e04026aee1cf884e27e3e42025-02-03T01:07:33ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972019-01-01201910.1155/2019/43832694383269Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical ObservationsSherif Elhosseiny0Hassan Al Moussawi1Jean M. Chalhoub2James Lafferty3Liliane Deeb4The Department of Medicine at Staten Island University Hospital, Northwell Health, USAThe Department of Medicine at Staten Island University Hospital, Northwell Health, USAThe Department of Medicine at Staten Island University Hospital, Northwell Health, USAThe Department of Cardiology at Staten Island University Hospital, Northwell Health, USAThe Department of Gastroenterology at Staten Island University Hospital, Northwell Health, USAThe introduction of Direct Oral Anticoagulants (DOACs) to the pharmaceutical market provided patients and clinicians with novel convenient and safe options of anticoagulation. The use of this class of medications is currently limited to venous thromboembolic therapy and prophylaxis, in addition to stroke prophylaxis in patients with nonvalvular atrial fibrillation. Despite their altered hemostasis, patients with cirrhosis are thought to be in a procoagulant state and thus prone to thrombus formation. Patients with cirrhosis might benefit from the convenience of DOACs; however, the medical literature includes limited data on the efficacy and safety of DOACs in this special patient population. The aim of this review is to summarize the current evidence for anticoagulation options in patients with cirrhosis and their safety profile.http://dx.doi.org/10.1155/2019/4383269 |
| spellingShingle | Sherif Elhosseiny Hassan Al Moussawi Jean M. Chalhoub James Lafferty Liliane Deeb Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations Canadian Journal of Gastroenterology and Hepatology |
| title | Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations |
| title_full | Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations |
| title_fullStr | Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations |
| title_full_unstemmed | Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations |
| title_short | Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations |
| title_sort | direct oral anticoagulants in cirrhotic patients current evidence and clinical observations |
| url | http://dx.doi.org/10.1155/2019/4383269 |
| work_keys_str_mv | AT sherifelhosseiny directoralanticoagulantsincirrhoticpatientscurrentevidenceandclinicalobservations AT hassanalmoussawi directoralanticoagulantsincirrhoticpatientscurrentevidenceandclinicalobservations AT jeanmchalhoub directoralanticoagulantsincirrhoticpatientscurrentevidenceandclinicalobservations AT jameslafferty directoralanticoagulantsincirrhoticpatientscurrentevidenceandclinicalobservations AT lilianedeeb directoralanticoagulantsincirrhoticpatientscurrentevidenceandclinicalobservations |